The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Visual abstract | Real-world use of blinatumomab in adult ALL
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
Based on results from the NEUF study, what would you expect the overall MRD response rate to be in adult patients with B-ALL who were MRD+ and received two cycles of blinatumomab?
A
B
C
D
The ALL Hub is pleased to present a visual abstract summarizing results from the NEUF study and other real-world studies assessing the efficacy of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia (B-ALL).
These studies confirmed the efficacy of blinatumomab in real-world patients with B-ALL, including measurable residual disease-positive patients, relapsed/refractory patients, patients in first and second complete remission, and newly diagnosed patients.1–3
Your opinion matters
I commit to reviewing the latest clinical data and recommendations for the optimal use of blinatumomab in adult patients with B-ALL.
This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?
